CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary Immunodeficiency

Inclusion Criteria: * profound combined immunodeficiency * cytomegalovirus (CMV) infection * viremia * pneumonia Exclusion Criteria: * Receiving a steroid dose of ≥ 0.5 mg/kg of prednisolone equivalent * Receiving antithymocyte globulin or similar anti-T-cell antibody therapy, methotrexate, or other antimetabolite-type immunosuppressants that are toxic to proliferating T cells, and extracorporeal * Receiving checkpoint inhibitor agents (eg, nivolumab, pembrolizumab, ipilimumab) are within 3 drug half-lives of the most recent dose to cycle 1 day 1. * Administration of another investigational product